Comparison of the Farr radioimmunoassay, 3 commercial enzyme immunoassays and Crithidia luciliae immunofluorescence test for diagnosis and activity assessment of systemic lupus erythematosus

Clinica Chimica Acta

Volumn 411, Issue 13-14, 2010, Pages 959-964

  Launay, David ^a   Schmidt, Jean ^a   Lepers, Sébastien ^b   Mirault, Tristan ^a   Lambert, Marc ^a   Kyndt, Xavier ^c   Reumaux, Dominique ^c   Duhamel, Alain ^d   Hachulla, Eric ^a   Hatron, Pierre Yves ^a   Prin, Lionel ^a   Dubucquoi, Sylvain ^a  

^a UNIV LILLE   (France)

^b Laboratoire d'Analyse de Biologie Médicale   (France)

^c CENTRE HOSPITALIER DE VALENCIENNES   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Activity assessment; Anti dsDNA antibodies assays; Diagnosis; Systemic lupus erythematosus

Indexed keywords

DOUBLE STRANDED DNA ANTIBODY;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DECISION MAKING; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE COURSE; ENZYME IMMUNOASSAY; FEMALE; HUMAN; IMMUNOFLUORESCENCE TEST; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RHEUMATIC DISEASE; SENSITIVITY AND SPECIFICITY; SYSTEMIC LUPUS ERYTHEMATOSUS;

CRITHIDIA LUCILIAE;

EID: 77952544765     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.03.016     Document Type: Article

References (28)

1. D'Cruz D.P., Khamashta M.A., Hughes G.R. Systemic lupus erythematosus. Lancet 2007, 369:587-596.
2. Riboldi P., Gerosa M., Moroni G., et al. Anti-DNA antibodies: a diagnostic and prognostic tool for systemic lupus erythematosus?. Autoimmunity 2005, 38:39-45.
3. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997, 40:1725.
4. Esdaile J.M., Abrahamowicz M., Joseph L., MacKenzie T., Li Y., Danoff D. Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus. Why some tests fail. Arthritis Rheum 1996, 39:370-378.
5. Walz LeBlanc B.A., Gladman D.D., Urowitz M.B. Serologically active clinically quiescent systemic lupus erythematosus-predictors of clinical flares. J Rheumatol 1994, 21:2239-2241.
6. Rouquette A.M., Desgruelles C. Detection of antibodies to dsDNA: an overview of laboratory assays. Lupus 2006, 15:403-407.
7. Solomon D.H., Kavanaugh A.F., Schur P.H. American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines. Related articles, links evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum 2002, 47:434-444.
8. Tzioufas A.G., Terzoglou C., Stavropoulos E.D., Athanasiadou S., Moutsopoulos H.M. Determination of anti-ds-DNA antibodies by three different methods: comparison of sensitivity, specificity and correlation with lupus activity index (LAI). Clin Rheumatol 1990, 9:186-192.
9. Werle E., Blazek M., Fiehn W. The clinical significance of measuring different anti-dsDNA antibodies by using the Farr assay, an enzyme immunoassay and a Crithidia luciliae immunofluorescence test. Lupus 1992, 1:369-377.
10. Yu L., Wang J., O'Dell J.R., Oates J., Arend W.P., Eisenbarth G.S. Anti-dsDNA antibody assay: high specificity and sensitivity with a filtration radioassay in comparison to low specificity with the standard ELISA. J Rheumatol 2007, 34:734-739.
11. Neogi T., Gladman D.D., Ibanez D., Urowitz M. Anti-dsDNA antibody testing by Farr and ELISA techniques is not equivalent. J Rheumatol 2006, 33:72-73.
12. Gladman D.D., Ibanez D., Urowitz M.B. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002, 29:288-291.
13. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
14. Vitali C., Bombardieri S., Jonsson R., et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002, 61:554-558.
15. LeRoy E.C., Black C., Fleischmajer R., et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988, 15:202-205.
16. Bohan A., Peter J.B. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975, 292:344-347.
17. Derksen R.H., Bast E.J., Strooisma T., Jacobs J.W. A comparison between the Farr radioimmunoassay and a new automated fluorescence immunoassay for the detection of antibodies against double stranded DNA in serum. Ann Rheum Dis 2002, 61:1099-1102.
18. Bootsma H., Spronk P., Derksen R., et al. Prevention of relapses in systemic lupus erythematosus. Lancet 1995, 345:1595-1599.
19. Tseng C.E., Buyon J.P., Kim M., et al. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006, 54:3623-3632.
20. Bootsma H., Spronk P.E., ter Borg E.J., et al. The predictive value of fluctuations in IgM and IgG class anti-dsDNA antibodies for relapses in systemic lupus erythematosus. A prospective long-term observation. Ann Rheum Dis 1997, 56:661-666.
21. Vermeersch P., Coenen D., Geboes K., Marien G., Hiele M., Bossuyt X. Use of likelihood ratios improves clinical interpretation of IgA anti-tTG antibody testing for celiac disease. Clin Chim Acta 2010, 411:13-17.
22. Bossuyt X. Clinical performance characteristics of a laboratory test. A practical approach in the autoimmune laboratory. Autoimmun Rev 2009, 8:543-548.
23. Lefranc D., Launay D., Dubucquoi S., et al. Characterization of discriminant human brain antigenic targets in neuropsychiatric systemic lupus erythematosus using an immunoproteomic approach. Arthritis Rheum 2007, 56:3420-3432.
24. Isenberg D.A., Dudeney C., Williams W., et al. Measurement of anti-DNA antibodies: a reappraisal using five different methods. Ann Rheum Dis 1987, 46:448-456.
25. ter Borg E.J., Horst G., Hummel E.J., Limburg P.C., Kallenberg C.G. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum 1990, 33:634-643.
26. Smeenk R.J., Berden J.O., Swaak A.J. ds-DNA antibodies. Autoantibodies 1996, 227-236. Elsevier. J.B. Peter, Y. Shoenfeld (Eds.).
27. Conrad K., Ittenson A., Reinhold D., et al. High sensitive detection of double-stranded DNA autoantibodies by a modified Crithidia luciliae immunofluorescence test. Ann N Y Acad Sci 2009, 1173:180-185.
28. Li Y., Tucci M., Narain S., Barnes E.V., Sobel E.S., Segal M.S. Urinary biomarkers in lupus nephritis. Autoimmun Rev 2006, 5:383-388.